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Abstract: Picornaviridae represent a very large family of small RNA viruses, some of 
which are the cause of important human and animal diseases. Since no specific therapy 
against any of these viruses currently exists, palliative symptomatic treatments are 
employed. The early steps of the picornavirus replicative cycle seem to be privileged 
targets for some antiviral compounds like disoxaril and pirodavir. Pirodavir’s main 
weakness is its cytotoxicity on cell cultures at relatively low doses. In this work some 
original synthetic compounds were tested, in order to find less toxic compounds with an 
improved protection index (PI) on infected cells. Using an amino group to substitute the 
oxygen atom in the central chain, such as that in the control molecule pirodavir, resulted in 
decreased activity against Rhinoviruses and Polioviruses. The presence of an -ethoxy-
propoxy- group in the central chain (as in compound I-6602) resulted in decreased cell 
toxicity and in improved anti-Rhinovirus activity. This compound actually showed a PI 
>700 on HRV14, while pirodavir had a PI of 250. These results demonstrate that 
modification of pirodavir’s central hydrocarbon chain can lead to the production of novel 
derivatives with low cytotoxicity and improved PI against some strains of Rhinoviruses. 
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1. Introduction 
The viruses in the Picornaviridae family cause an extraordinarily wide range of illnesses [1-4]. The 
syndromes associated with these agents include asymptomatic infection, aseptic meningitis syndrome 
(the most common acute viral disease of the CNS), colds, febrile illness with rash, conjunctivitis, 
herpangina, muscle infection, heart infection, and hepatitis. Aseptic meningitis is most common in 
very young infants. Myocarditis and pleurodynia are most prevalent in adolescents and young adults. 
Two major human genera of Picornaviridae, the Enteroviruses and Rhinoviruses, have an identical 
morphology but can be distinguished through clinical, biophysical, and epidemiological studies. The 
picornavirus viral capsid consists of a densely packed icosahedral arrangement of 60 protomers [5]. 
Each protomer consists of four polypeptides – VP 1, 2, 3, and 4 – which all derive from the cleavage 
of a larger protein. The capsid-coat protein serves multiple functions, including: (a) protecting the viral 
RNA from degradation by environmental RNAse, (b) selecting and packaging viral RNA, (c) 
penetrating target cells and delivering the viral RNA into the cell cytoplasm, and (d) determining host 
and tissue tropism by recognition of cell-specific cell-membrane receptors. The virus uses these 
membrane receptors to enter the target cells [6]. For example, most human Rhinovirus strains bind to 
the intracellular adhesion molecule 1 (ICAM-1), an immunoglobulin-like molecule, even though some 
use a low-density lipoprotein receptor [5]. Some of the picornavirus families may use the same 
receptor which could be shared with unrelated viruses [7,8]. 
Specific antiviral agents for the treatment of picornavirus infections are not available [9-12]. Due to 
the lack of specific antiviral therapy, most enteroviral illnesses are managed symptomatically. 
Although effective antiviral therapy is not yet clinically available, some promising anti-picornavirus 
drugs reduce the duration of illness among adults with enteroviral aseptic meningitis [3,4,9,13].  
Disoxaril was the first capsid-blocker compound to enter a phase-1 clinical trial; it was shown to 
have moderate activity against the Rhinoviruses and strong activity against the Enteroviruses, both in 
vitro and in vivo; however, additional clinical studies demonstrated high in vivo toxicity and the 
compound did not undergo further development. [14-16]. Pleconaril is a new-generation capsid-
blocker with a broad spectrum against several Enteroviruses and Rhinoviruses, but the presence of 
some important side-effects have blocked its clinical use [13,17]. Other “capsid-binding” compounds 
are pirodavir and its derivatives, which have proved to be effective in intranasal treatment of patients 
with a common cold caused by some strains of human Rhinoviruses [18].  
In this study we tested several novel anti-rhinovirus compounds and demonstrated that some 
modifications of the central hydrocarbon chain of the molecules could lead to new interesting drugs 
with an improved activity for certain Rhinovirus strains and a decreased cytotoxicity on cell cultures. 
2. Results and Discussion 
2.1. Anti-rhinovirus activity  
The molecular formulae of the tested compounds are indicated in Figure 1. Compounds I-6002, I-
6230, I-6232 showed poor activity on Rhinoviruses (Table 1), with a protection index (PI) from 1 to 4 
on HRV14, although substance I-6232 resulted as being far less toxic than pirodavir (50.0 μg/mL 
against 3.1, respectively). Also I-6273, I-6373 and I-6473 showed limited antiviral activity against 
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HRV14, with a PI varying from 4 to 16, and from 8 to 33 on HRV39. However, the modifications in 
the I-6273 molecule, with the insertion of a methylisoxazol group, resulted in decreased cell toxicity 
on HeLa cells (50.0 μg/mL) as compared to pirodavir. Substance I-6501 showed a PI of 4 on HRV14 
and of 40 on HRV39, whereas compounds I-6502, I-6602 and I-6702 were the most active anti-
Rhinovirus molecules tested in this study; I-6502 scored a PI of 83 on HRV14 and of 178 on HRV39; 
I-6602 showed an effective dose of 0.07 μg/mL on HRV14 and HRV39, with a PI of 714 on both virus 
strains. The last compound tested (I-6702) displayed low toxicity with a cytotoxic dose (CD) of  
50 μg/mL and a PI of 714 on HRV14 and of 143 on HRV39; however due to its poor stability, these 
results were not always repeatable, probably because this compound was inactivated by cellular 
enzymes. The active anti-Rhinovirus concentrations of pirodavir were 0.012 μg/mL on HRV14 and 
0.006 on HRV39, respectively. Although the specific activity of pirodavir resulted as being greater 
than that of the novel derivatives, the PI of compound I-6602 (= 714) was found to be more than 
twofold that of pirodavir (= 250), since it was less toxic to HeLa cell cultures (50.0 against 3.1 
μg/mL). These compounds all showed poor activity on Polio 1, with inhibiting doses (ID) from 1.99 to  
2.65 µg/mL.    
Figure 1. Molecular structures of pirodavir, pleconaril and the novel synthetic compounds. 
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Table 1. Screening of cytotoxic activity and anti-Rhinovirus properties of the novel 
compounds and the control Pirodavir. 
Compounds 
Cytotoxic 
activity 
Anti-Rhinovirus activity 
Anti-Poliovirus  
Activity 
aCD50 
 μg/mL 
 HRV14 
 bID 50 
μg/mL 
cPI 
 
HRV39 
ID50 μg/mL 
PI ID50 
μg/mL 
PI 
I-6002 1.5 1.5 1 1.5 1 >1.5 <1 
I-6230 6.0 6 1 3.1 2 0.5 12 
I-6232 50.0 12.5 4 3.1 16 0.7 71 
I-6273 50.0 3.1 16 1.5 32 1.4 35 
I-6373 12.5 1.5 8 0.37 33 1.4 9 
I-6473 6 1.5 4 0.75 8 1.4 4 
I-6501 6 1.5 4 0.15 40 2.0 3 
I-6502 12.5 0.15 83 0.07 17 2.6 4.8 
I-6602 50 0.07 714 0.07 714 1.9 26 
I-6702 50 0.07 714 0.35 142 9.1 5.5 
PIRODAVIR 3.1 0.012 250 0.006 500 0.1 31 
a CD: Cytotoxic dose on HeLa cells; b ID: Inhibitory dose; c PI: Protection index (CD/ID). 
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Therefore the addition of an -ethoxy-propoxy- group in the central chain, such as in I-6602, 
produced a compound with low toxicity on cell cultures, but endowed with strong anti-Rhinovirus 
activity. Although the specific pirodavir activity was still superior to the I-6602 compounds, its 
toxicity, one of the main causes of pirodavir failure in clinical use, resulted in a much lower PI.  
The derivatives containing a -thioether- moiety in the central chain (6373,6501) showed poor 
activity against Rhinoviruses, suggesting that the large size of this atom, as compared to that of 
oxygen, may perhaps lead to difficulty in compound interaction with the VP1-viral canyon adhesin [7]. 
Moreover, the substitution of the oxygen atom in the central chain with a secondary amino moiety 
(6002, 6230, 6232, 6273) resulted in a general decrease in the antiviral activity of the tested 
compounds on Rhinoviruses. In addition, one of the novel tested compounds (I-6232) showed better 
inhibitory activity than pirodavir on Polio 1 (Table 1). It was also observed that modification in the left 
moiety of the pirodavir molecule (Figure 1) with the substitution of the methyl-pyridazinyl-piperidinyl 
group with other chemical entities, such as in I-6232 and I-6602, could lead to the production of 
compounds whose cytotoxic activity was 10–15 times lower than pirodavir’s. 
Two important findings were obtained from this study: firstly, some original derivatives, less toxic 
on cell cultures than pirodavir, were designed and tested leading to highly improved protection indexes 
on Rhinovirus infected cells as compared to the control molecule; secondly, the modification of the 
central chain of the pirodavir molecule, with the substitution of the –oxy- group or the addition of a 
second oxy or amino moiety, allowed the production of several molecules with extremely variable 
activity on the different strains of Rhinoviruses tested; some were almost ineffective, while others 
were very active against HRV14 and HRV39, with inhibiting properties sometimes much stronger than 
pirodavir’s.    
2.2. Time-addiction effect of some novel compounds on HRV14  
In the time-addiction assay the I-6602 compound only exerted its anti-Rhinovirus activity in the 
first hour after infection, similar to pirodavir, with an inhibition peak on HRV14 within about 45 min  
(Figure 2).  
Figure 2. Time-addiction effect of compounds I-6602 (0.5 µg/mL) and pirodavir  
(0.5 µg/mL) on HRV14 at various times of incubation during the viral replicative cycle. 
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The time addiction tests revealed that most of the novel compounds behaved like pirodavir and only 
inhibited Rhinovirus growth and multiplication in the early phases of viral reproduction. This confirms 
the established finding that pirodavir along with its derivatives could interfere with virion adhesion to 
the cell receptors (e.g. ICAM-1) [7,19]. 
3. Experimental 
3.1. Compounds 
The compounds tested in this work were designed and synthesized by IFI SpA (Rome) and were 
indicated with the following numbers:  
I-6002, (ethyl 4-(2-(biphenyl-4-yl)ethylamino)benzoate),  
I-6230 (ethyl 4-(4-(pyridazin-3yl)phenethylamino)benzoate),  
I-6232 (ethyl 4-(4-(6-methylpyridazin-3yl)phenethylamino)benzoate), 
I-6273 (ethyl 4-(4-(methylisoxazol-5-yl)phenethylamino)benzoate), 
I-6373 (ethyl 4-(4-(3-methylisoxazol-5-yl)phenethylthio)benzoate),  
I-6473 (ethyl 4-(4-(3-methylisoxazol-5-yl)phenethoxy)benzoate), 
I-6501 (ethyl 4-(5-(3-methylisoxazol-5-ylamino)pentylthio)benzoate), 
I-6502 (ethyl 4-(5-(3-methylisoxazol-5-ylamino)pentyloxy)benzoate),  
I-6602 (ethyl 4-(3-(2-(3-methylisoxazol-5-yl)ethoxy)propoxy)benzoate), 
I-6702 (ethyl 4-(3-(1,3-dioxo-3,4-dihydroisoquinolin-2(1H)-yl)propoxy)benzoate). 
All these compounds were designed using the basic structure of both pirodavir and pleconaril as a 
model (see Figure 1), with substantial modifications in the central hydrocarbon chain (the oxy group 
was either substituted by a thioether or a secondary amino moiety) and in the pyridazinyl-piperidinyl 
moiety (left side in Figure 1). In some substances the methyl-isoxazol group present in the pleconaril 
molecule was added (Figure 1). Pirodavir (R 77975) [20] was kindly provided by the Janssen Research 
Foundation (Beerse, Belgium) and was used as a control in the various tests. The drugs were dissolved 
in DMSO at a concentration of 25 mg/mL and then stored in a refrigerator until use.  
3.2. Cells and viruses 
The cytotoxic and antiviral activity of the compounds was performed on both the HeLa cells (Ohio 
strain) and the Hep-2 cells grown in DMEM with 1% non essential aminoacids, 200 μg/mL 
streptomycin, 200 units/mL penicillin G and 10% foetal calf serum (GIBCO Laboratories INC). Cell 
lines were kept at 37 °C in a humidified atmosphere with 5% CO2. The Rhinoviruses HRV14 (group 
A) and HRV39 (group B) and the Poliovirus strain Sabin 1, were purchased from the American Type 
Culture Collection (ATCC). For all the above mentioned viruses, working stocks were prepared as 
cellular lysates using DMEM with 2% heat inactivated fetal calf serum. 
3.3. Cytotoxic activity 
The cytotoxicity of the test compounds was evaluated by measuring the effect produced on cell 
morphology and cell growth in vitro. Cell monolayers were prepared in 24-well tissue culture plates 
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and exposed to various concentrations of the compounds. Plates were checked by light microscopy 
after 24, 48 and 72 h. Cytotoxicity was scored as morphological alterations (e.g. rounding up, 
shrinking, detachment). The viability of the cells was determined by a tetrazolium-based colorimetric 
method using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), as previously 
described [21,22]. The 50% cytotoxic dose (CD50) is the concentration of the compound that reduced 
the absorbance of the control sample by 50%.  
3.4. Inhibition of viral multiplication 
The Rhinovirus inhibition assay was evaluated by a one-step viral infection of cell monolayers and 
then by virus yield titration in an agar-plaque assay. HeLa cell monolayers were prepared in 24 
multiwell plates and were infected by the Rhinoviruses at a MOI of 1. Then serial dilutions of the test 
compounds were added and after 24–36 h of incubation at 33 °C and 3% CO2, when the cytopathic 
effect in the control cells was almost total, the monolayers were frozen and thawed and viruses in the 
supernatant were titrated by the plaque assay method. The assay of the antiviral activity of Poliovirus 
was carried out by the 50% plaque reduction assay in Hep2 cells as previously described [23]. The 
compound concentration required to inhibit virus plaque formation by 50% is expressed as the 50% 
inhibitory concentration (ID50) and calculated by dose-response curves and linear regression. 
3.5. Time-reduction studies of virus yield 
Time-reduction studies were performed on cell monolayers grown in 24 well plates. The 
compounds were added to the cells from time 0 to time +6 after viral infection. The cells were 
incubated in a CO2 atmosphere for 24–36 h, washed twice with HBSS and then the virus yield was 
detected by plaque assay.  
4. Conclusions   
This study confirms that the central chain of pirodavir and its derivatives seems to be the crucial 
part of these molecules for exerting a specific anti-Picornavirus activity. This behaviour can be due to 
the different structure of the “canyon” formed by the VP1 protein of the various species of 
Picornavirus strains [10]. Thus, considering that the VP1 viral canyons of different species of 
Picornaviruses have a peculiar structure in terms of size, depth and shape, we are designing novel SAR 
studies targeted to modify the central chain of new derivatives of compound I-6602, with the aim of 
finding original molecules that can better adapt inside these canyons, with a further possible 
improvement of their antiviral properties against the single Rhinovirus strains and hopefully also 
against other Picornavirus species. Finally, additional tests still have to be performed to define the 
stability and bio-availability of these newly synthesized compounds.         
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